Founded in 2006, Windham Venture Partners is a New York City based venture capital firm focused on healthcare, with a particular emphasis on medical technology (devices and diagnostics) and healthcare IT / digital health. Windham seeks to invest in and partner with companies that are commercializing game-changing technologies to serve unmet needs in order to improve the lives of large numbers of patients and yield robust returns for its investors.
For more information, please visit: www.windhamvp.com
Carolyn Ng, Ph.D., is Managing Director at Vertex Ventures HC. At Vertex Ventures HC, Carolyn is responsible for driving venture investments across biotechnology, medical devices, and health technology fields. Carolyn currently serves on the Board of Directors for Obsidian Therapeutics, Twentyeight-Seven Therapeutics, Bicycle Therapeutics (NASDAQ: BCYC), and Nuvaira. She was also a Board Observer for Visterra (acquired by Otsuka Pharmaceutical for $430 M) and Earlens. She has previously closely supported Vertex’s investment into Twelve (acquired by Medtronic for $458 M). Working across the U.S., Europe, and Asia, she plays an active role in expanding the geographical reach of Vertex HC and its portfolio companies for cross-border collaborations, business development, and syndication.
She started her healthcare training in the oncology pharmacy department of the National University Cancer Institute of Singapore, where first-hand clinical experience inspired her to pursue scientific research in oncology. As an oncology scientist, she is deeply passionate about innovation that impacts patients’ lives. Prior to joining Vertex, Carolyn was a pharma strategy consultant at Deallus Consulting, a specialized London-headquartered life sciences consulting firm.
Carolyn holds a Ph.D. in Cancer Molecular Biology from the National University of Singapore Graduate School for Integrative Sciences and Technology (NGS), where she was a recipient of the prestigious NGS Ph.D. Scholarship. She also holds a B.S. degree in Pharmacy with First Class Honors from the National University of Singapore, where she received the PSS Prize for Pharmaceutics awarded to the top graduating student in the class.
Hank is a General Partner of Lightstone Ventures. He focuses on medical device investments out of the firm’s Menlo Park, CA office. Hank also serves as a General Partner at Morgenthaler Ventures which he joined in 2007 after more than 25 years in the life science industry. Prior to becoming a venture capitalist, he co-founded eight medical device companies. He has served as a director for nine companies that have had successful exits with a combined value in excess of $3 billion.
In August 2015, Medtronic announced plans to acquire Twelve, Inc. for $408 million and milestone payments of $50 million. In May 2014, Cardinal Health completed the acquisition of Access Closure for $320 million. In June 2014, Ulthera, Inc. acquired Cabochon Aesthetics in cash and milestone payments. Hank served as a board member of the three companies.
In 2011, Medtronic completed the acquisition of Ardian for $800 million. Hank was a founder, helped incubate Ardian while at The Foundry, and served as a Director of the company. In 2010, Hank was a board member during the $785 million acquisition of Acclarent by Johnson & Johnson.
Hank led the Lightstone investment and serves on the board of Earlens and Claret. He also serves on the boards of Morgenthaler portfolio companies – Holaira, Kona Medical, Miramar Labs and Setpoint.
From 2000-2007 Hank served as Vice-Chairman of The Foundry where he co-founded Ardian, Cabochon Aesthetics, ForSight Labs, ForSight Vision2, Miramar Labs, and Transcend. From 1993 to 2000, he served as President and CEO of Perclose, Inc., where he led the company to $100 million in sales, a successful IPO and a $680 million acquisition in 1999 by Abbott Laboratories. He was Chairman of Embolic Protection, where he helped negotiate the acquisition of the company in 2001 by Boston Scientific. He also served as a Director at TransVascular until Medtronic acquired the company in 2003. Previously, Hank worked at Eli Lilly for 12 years in various management positions.
Kirk Nielsen is a Managing Partner at Vensana Capital. Kirk co-founded Vensana as a Managing Director at Versant Ventures, where he led the firm's medtech practice. He joined Versant in 2006 from Medtronic, where he worked in sales & marketing in the company’s Cardiac Rhythm Management division. Previously, he spent time at Fluidigm (a Versant portfolio company) and he also served as a consultant at Bain & Company, where he advised clients in healthcare, private equity, and other industries. Prior to his business career, Kirk was a professional hockey player. At Versant, Kirk led or co-led investments in numerous companies that have successfully exited, including Biotie Therapies, Cameron Health, CardiAQ, Ceterix Orthopaedics, Lutonix, NeuWave Medical, and Sequent Medical, and he remains active with Inari Medical, Metavention, Monteris Medical, Nuvaira, Respicardia, and Veran Medical. Kirk graduated with a BA in Biology from Harvard College, where he won the John P. Reardon award as the school's top scholar-athlete, and he earned an MBA from Harvard Business School, where he was a Baker Scholar.